{"id":"W1997512486","doi":"10.1136/thoraxjnl-2011-201054c.252","title":"P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial","year":2011,"lang":"en","type":"article","venue":"Thorax","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Minimal clinically important difference; COPD; Muscarinic antagonist; Lama; Placebo; Internal medicine; Inhaler; Dry-powder inhaler; Quality of life (healthcare); Exacerbation; Anesthesia; Randomized controlled trial; Asthma; Antagonist","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004539452,0.0001814061,0.00027072,0.00009163867,0.0003091511,0.00006430748,0.0001341292,0.0001147145,0.0002512317],"category_scores_gemma":[0.0005987862,0.0001315789,0.00006623995,0.0002799699,0.0005576092,0.0002083142,0.0001213853,0.0002624827,0.00002396571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000150652,"about_ca_system_score_gemma":0.0002952945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002782114,"about_ca_topic_score_gemma":0.0000268507,"domain_scores_codex":[0.9984845,0.0001838919,0.0002725408,0.0003599848,0.0003731204,0.0003259419],"domain_scores_gemma":[0.9989128,0.0002246308,0.0001098904,0.000352419,0.000183309,0.0002170054],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05205076,0.007389177,0.2434221,0.00148814,0.005318074,0.000410573,0.04798165,0.000003731433,0.04236445,0.04277289,0.05394658,0.5028518],"study_design_scores_gemma":[0.01937273,0.0009726778,0.968053,0.0001605754,0.0004963673,0.00002943428,0.003092696,0.0005203855,0.001143536,0.003598024,0.00221312,0.0003474028],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865708,0.00316338,0.000007937782,0.001374389,0.0002318622,0.001374842,0.00007267299,0.00008672572,0.007117377],"genre_scores_gemma":[0.995845,0.0003450704,0.0001533382,0.0001177599,0.0002769432,0.0001459407,0.00005676284,0.00002978585,0.003029383],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.724631,"threshold_uncertainty_score":0.5365632,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03614344810495717,"score_gpt":0.301206005092894,"score_spread":0.2650625569879368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}